Search

Showing "11155" results for ""

Rifampicin levels strongly reduced in patients with TB and diabetes

Study challenges current thinking regarding viral load as a predictor of CD4 cell loss

Ninth English HIV transmission conviction for Merseyside man

South Africa: authorities rush to control illegal medicines boom

HIV prevalence among young women in Botswana falls to lowest level since early 1990s, but still high

No lipid increase with Merck integrase inhibitor at 24 weeks

No fat loss with tenofovir after five years

Botswana mounts one of the most successful national responses to HIV/AIDS — but can it maintain the momentum?

Treatment of acute hepatitis C produces good response rates in HIV-positive patients

HIV/HCV co-infected patients respond to re-treatment with pegylated interferon plus ribavirin

16% of drug-naive entering GSK US studies already have resistance

Nevirapine hepatotoxicity after treatment switch no more likely at higher CD4 counts

Suspected abacavir hypersensitivity less likely to be diagnosed in people of African ethnicity

Trizivir non-inferior to unboosted atazanavir in treatment-naive

MK-0518: three-quarters of highly treated patients have undetectable viral load at 24 weeks

Novel NRTI elvucitabine active against HIV in a 7-day monotherapy study

Boosted fosamprenavir and atazanavir show comparable potency, tolerability in treatment-naive

Antibody to CCR5 receptor safe, effective, suitable for weekly dosing, preliminary study shows

Receive the latest HIV research and conference news

Showing "11155" results for ""

Rifampicin levels strongly reduced in patients with TB and diabetes

Study challenges current thinking regarding viral load as a predictor of CD4 cell loss

Ninth English HIV transmission conviction for Merseyside man

South Africa: authorities rush to control illegal medicines boom

HIV prevalence among young women in Botswana falls to lowest level since early 1990s, but still high

No lipid increase with Merck integrase inhibitor at 24 weeks

No fat loss with tenofovir after five years

Botswana mounts one of the most successful national responses to HIV/AIDS — but can it maintain the momentum?

Treatment of acute hepatitis C produces good response rates in HIV-positive patients

HIV/HCV co-infected patients respond to re-treatment with pegylated interferon plus ribavirin

16% of drug-naive entering GSK US studies already have resistance

Nevirapine hepatotoxicity after treatment switch no more likely at higher CD4 counts

Suspected abacavir hypersensitivity less likely to be diagnosed in people of African ethnicity

Trizivir non-inferior to unboosted atazanavir in treatment-naive

MK-0518: three-quarters of highly treated patients have undetectable viral load at 24 weeks

Novel NRTI elvucitabine active against HIV in a 7-day monotherapy study

Boosted fosamprenavir and atazanavir show comparable potency, tolerability in treatment-naive

Antibody to CCR5 receptor safe, effective, suitable for weekly dosing, preliminary study shows

Receive the latest HIV research and conference news